sofosbuvir/velpatasvir / Generic mfg. - LARVOL DELTA

MINMON-J: Implementing Low-Barrier HCV Treatment in a Jail Setting (clinicaltrials.gov) - P4 | N=40 | Recruiting | Sponsor: Lifespan | Not yet recruiting ➔ Recruiting

Enrollment open • Hepatitis C • Infectious Disease • Inflammation

A Case of Primary Hepatocellular carcinoma with a 12cm Contralateral Indeterminate Left Adrenal mass. (ENDO 2025) - "Case Description:A 71-year-old male with a medical history of compensated Hepatitis C cirrhosis on Epclusa/Ribavirin was undergoing computed tomography (CT) of chest due to a smoking history and known pulmonary nodules. Serum steroid precursors can be utilized to differential primary adrenal cortical carcinoma versus other adrenal malignancies or metastases. Adrenal biopsy can be considered in select cases of indeterminate adrenal masses with known history of extra-adrenal malignancy, but pheochromocytoma must be ruled out prior."

Clinical • Adrenal Cortex Carcinoma • Endocrine Cancer • Fibrosis • Genito-urinary Cancer • Hepatitis C • Hepatocellular Cancer • Hepatology • Immunology • Infectious Disease • Oncology • Solid Tumor

C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV (clinicaltrials.gov) - P3 | N=880 | Recruiting | Sponsor: Atea Pharmaceuticals, Inc.

New P3 trial • Hepatitis C • Infectious Disease • Inflammation

Pretreatment serum angiopoietin-2 predicts prognosis and liver functional reserve after successful HCV eradication with sofosbuvir and velpatasvir in patients with HCV-related decompensated cirrhosis. (PubMed, J Gastroenterol) - "Pretreatment Ang2 levels predict survival and liver functional reserve after SVR in HCV-related decompensated LC."

Journal • Fibrosis • Gastroenterology • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis • ANGPT2

Effects of Sofosbuvir/Velpatasvir Therapy on Extrahepatic Manifestations in Patients With Type 2 Diabetes and Chronic Hepatitis C: Insights From a Nationwide Hepatitis C Virus Registry in Taiwan. (PubMed, Kaohsiung J Med Sci) - "Multivariate analysis identified fasting glucose levels and diabetes status as significant factors associated with HbA1c decline. These findings suggest that successful HCV treatment can improve glycemic control, highlighting the need for collaboration between hepatology and non-hepatology specialists in patient care."

Journal • Diabetes • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • Type 2 Diabetes Mellitus

Chronic Hepatitis C Treatment Failure With Crushed Sofosbuvir/Velpatasvir in a Patient With Total Parenteral Nutrition-dependent Short Bowel Syndrome. (PubMed, J Pharm Pract) - "We present the case of a 61-year-old patient infected with chronic hepatitis C virus (HCV) genotype 3, F1 fibrosis and history of short bowel syndrome, dependent on total parenteral nutrition (TPN) who was referred to the clinical pharmacist for HCV treatment. Following 12 weeks of treatment with crushed, orally administered sofosbuvir/velpatasvir (SOF/VEL) the patient was unable to achieve sustained virologic response (SVR12), suggesting that this therapy may be ineffective in patients with short bowel syndrome."

Journal • Fibrosis • Gastrointestinal Disorder • Hepatitis C • Immunology • Infectious Disease • Inflammation • Short Bowel Syndrome

Prevalence, clinical correlations and outcomes of Cryoglobulinemic Vasculitis: a retrospective monocentric study (2013–2023) (EULAR 2025) - "Since the introduction of pan-genotypic regimens for the treatment of HCV in 2017 (e.g., Sofosbuvir/Velpatasvir and Glecaprevir/Pibrentasvir), the mean incidence of CV decreased from 8.4 cases (±1.7) during the period 2013–2017 to 3 cases (±1.6) during the period 2018–2023 ( p-value 0.001 )...Two-thirds of patients with CryoVas related to ADs received Rituximab (RTX), while Belimumab (BEL) was used exclusively in CryoVas related to ADs and essential CryoVas (10% and 8%, respectively)... CryoVas remains a significant clinical condition, with its etiology progressively evolving in recent years. Treatment approaches varied by etiology, with RTX serving as a cornerstone for CryoVas associated with ADs, while BEL demonstrated potential in select cases. Despite advancements in treatment and high rate of complete clinical response, relapse rates remain high, particularly in autoimmune-related CryoVas."

Retrospective data • Cardiovascular • Glomerulonephritis • Hematological Disorders • Hepatitis B • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Lupus Nephritis • Nephrology • Rheumatology • Sjogren's Syndrome • Vasculitis

A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantation. (PubMed, JHLT Open) - "Episodes of bradycardia were transient, resolved with intervention, and did not require the discontinuation of SOF/VEL. In patients requiring the combination of SOF/VEL and amiodarone, consideration of therapeutic options is warranted prior to the addition of other bradycardia-inducing medications."

Journal • Cardiovascular • Hepatitis C • Infectious Disease • Inflammation • Transplantation

The experience and outcomes of our centre’s first year accepting Hepatitis C positive deceased donor kidneys for transplantation (UKKW 2025) - "She then underwent a 16-week course of Epclusa to ensure a sustained virological response at 12 weeks following completion of treatment (SV12), and has successfully achieved SV12 clearance...She completed a 16-week course of Maviret with sustained virological response and no second course of treatment required...Of those that have gone ahead, 2 of 5 patients have developed active viraemia and both of these have been successfully treated. We are encouraged by this small number of results and will continue with this programme in the hopes that more of our patients will consent to HCV-positive donor kidneys in future, with ongoing good outcomes."

Hepatitis C • Hepatology • Infectious Disease • Inflammation • Solid Organ Transplantation • Transplantation

SVR timelines in hepatitis - C irrespective of viral genotype: An Indian perspective. (PubMed, J Family Med Prim Care) - "Our findings suggest that hepatitis treatment duration varies based on Child-Pugh class and cirrhosis progression indicating the need for individualized treatment plans with tailored therapy durations. As most patients achieved SVR within 8 weeks, a shorter DAA regimen could be effective in the management of hepatitis C, warranting further research to optimize treatment timelines."

Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation

Clearance of Hepatitis C Viremia During Direct-Acting Antiviral Therapy Leads to Rapid Changes in Lipid and Lipoprotein Metabolism. (PubMed, Aliment Pharmacol Ther) - "Serum lipids and lipoproteins rapidly increase with inhibition of viral replication during DAA therapy, an effect that may be mediated by genes affecting hepatic de novo lipogenesis. Based on lipid changes, HCV eradication may increase CVD risk, but this needs to be investigated prospectively."

Journal • Cardiovascular • Dyslipidemia • Hepatitis C • Immunology • Infectious Disease • Inflammation • Metabolic Disorders • APOA1 • APOB

Treatment options to support the elimination of hepatitis C: an open-label, factorial, randomised controlled non-inferiority trial. (PubMed, Lancet) - "Sofosbuvir-daclatasvir was non-inferior to sofosbuvir-velpatasvir. High efficacy was seen with novel strategies, which might help to inform approaches to treatment for harder-to-reach populations."

Head-to-Head • Journal • Fibrosis • Hepatitis C • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

STORC: Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy (clinicaltrials.gov) - P4 | N=100 | Recruiting | Sponsor: Catherine Anne Chappell | Trial completion date: Dec 2025 ➔ Jun 2026 | Trial primary completion date: Jun 2025 ➔ Dec 2025

Trial completion date • Trial primary completion date • Hepatitis C • Infectious Disease • Inflammation

Treatment options to support the elimination of hepatitis C: an open label, factorial randomised controlled trial (EASL 2025) - "Background and aims: WHO recommends treating Hepatitis C infection with one of three antiviral combinations for 8 to 12 weeks, two of which (sofosbuvir/velpatasvir and sofosbuvir/daclatasvir) are widely used in low-income settings. SOF/DCV is non-inferior to SOF/VEL and is likely to have higher efficacy in this study. High efficacy was seen with three novel strategies that could improve treatment access for harder-to-reach populations."

Clinical • Late-breaking abstract • Fibrosis • Hepatitis C • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis

MINMON-J: Implementing Low-Barrier HCV Treatment in a Jail Setting (clinicaltrials.gov) - P4 | N=40 | Not yet recruiting | Sponsor: Lifespan

New P4 trial • Hepatitis C • Hepatology • Infectious Disease • Inflammation

TeleHCV: A single-visit protocol and minimal passive remote monitoring are sufficient to achieve high SVR with a sofosbuvir-velpatasvir regimen. (PubMed, Clinics (Sao Paulo)) - P=N/A | "This simplified strategy achieved a high SVR rate in a population with restricted access to specialized care. Telehealth tools and minimal monitoring are promising components for policies aimed at HCV elimination."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Changes in liver stiffness and steatosis in children after successful treatment with sofosbuvir/velpatasvir: Results of the PANDAA-PED study. (PubMed, Clin Exp Hepatol) - "However, its regression may occur to some extent after successful treatment with SOF/VEL. A transient increase in hepatic steatosis was observed after eradication of HCV, which requires further investigation."

Journal • Fibrosis • Hepatitis C • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Cirrhosis

Cost-Effectiveness of Screening and Treating Chronic Hepatitis C Virus Infection in Zimbabwe. (PubMed, Int J Environ Res Public Health) - "Screening for HCV among high-risk populations followed by treatment using sofosbuvir/velpatasvir is cost effective under the assumptions made in this study."

HEOR • Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Long-term prognosis and changes in liver function after direct-acting antiviral treatment in decompensated cirrhotic patients with hepatitis C virus (EASL 2025) - "All patients were treated with 12 weeks of sofosbuvir and velpatasvir... In decompensated cirrhotic patients with HCV treated with DAA, liver function improved up to 24 weeks after the EOT, but may deteriorate at 5 years after the EOT. The 5-year LT-free survival rate was 69.0%, and virologic response and Child-Pugh class at 12 weeks after the EOT were associated with LT-free survival."

Clinical • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Infectious Disease • Inflammation • Liver Cirrhosis • Oncology • Solid Tumor

Treatment of genotype 3 chronic hepatitis C infection: age reduces the efficacy of treatment with sofosbuvir and daclatasvir but the reduction is less marked with sofosbuvir and velpatasvir (EASL 2025) - "Efficacy with sofosbuvir/daclatasvir reduces by a modest amount with increasing age in Pakistan. This reduction is less marked but also seen in people with genotype 3 treated with sofosbuvir/velpatasvir in England. This likely reflects the higher rate of cirrhosis and co-morbidity in the elderly."

Clinical • Fibrosis • Hepatitis C • Hepatology • Infectious Disease • Inflammation

A decade of hepatitis C virus management: insights from a large population-based cohort on treatment patterns, adherence, and outcomes (EASL 2025) - "SVR rates were higher with newer pangenotypic regimens such as Epclusa (96.4%) and Maviret (96.2%) compared to older medications but markedly lower in DAA-experienced patients (85.0%) and those with moderate-to-low adherence (56.8%). This comprehensive decade-long analysis underscores critical insights into the management and outcomes of HCV in a large, population-based cohort, revealing that while high SVR rates are achievable, adherence remains a pivotal determinant of success. Our findings highlight specific subpopulations at risk for poor adherence and incomplete follow- up, emphasizing the need for targeted interventions to address these barriers in the pursuit of HCV eradication."

Adherence • Clinical • Addiction (Opioid and Alcohol) • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Depression • Diabetes • Fibrosis • Hepatitis C • Hepatocellular Cancer • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Major Depressive Disorder • Metabolic Disorders • Mood Disorders • Obesity • Oncology • Psychiatry • Solid Tumor

Healthcare resource use (HCRU) and cost impact of potential drug-drug interactions (DDIs) among HCV patients receiving Direct-Acting Antivirals (DAAs) concomitantly with antipsychotic drugs in the US (EASL 2025) - "We explored the use of antipsychotic drugs in a US claims database concomitantly with the use of any of the two pangenotypic DAAs, sofosbuvir/velpatasvir (SOF/VEL) or glecaprevir/pibrentasvir (GLE/PIB), evaluating the risk of associated DDIs, quality of the prescriptions based on the DDI risk, and the related healthcare resource use and costs. Despite the extended recognition of the use of the Liverpool HEP DDI tracker by all HCV treatment guidelines, this analysis of the DAAs based on the DDI risk demonstrates importance of safety monitoring of patients and the need for individualized medicine to ensure an appropriate DAA is used in patients with polypharmacy. Additionally, compared to GLE/PIB, SOF/VEL presents lower DDI risk and lower outpatient costs in the HCV patients receiving DAA treatment concomitantly with antipsychotic drugs."

Clinical • CNS Disorders • Hepatitis C

The SVR10K Hepatitis C study: final results show 98.9% SVR in 7,000 patients treated with SOF/VEL in Asia, Latin America, Middle East, Nordic and Southern Europe (EASL 2025) - "Background and Aims: A previously published real-world data analysis demonstrated high effectiveness of sofosbuvir/velpatasvir (SOF/VEL) in > 6,000 HCV patients from 12 clinical cohorts across Australia, Canada, Europe & USA... Results on treatment effectiveness in diverse geographical regions did not differ from real world studies of patients in Western countries, reinforcing the effectiveness of pangenotypic / panfibrotic / pangeographic DAA therapy such as SOF/VEL and supporting the global applicability of HCV treatment guidelines."

Clinical • CNS Disorders • Fibrosis • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation • Mental Retardation • Psychiatry

Health economic outcomes of a minimal monitoring approach to providing HCV therapy. (PubMed, Hepatol Commun) - "MINMON is a cost-saving strategy for HCV treatment, particularly in low- and middle-income country settings."

HEOR • Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation

Prescription patterns of comedications associated with drug-drug interactions risk in HCV-infected patients undergoing direct-acting antiviral treatment: an analysis of an administrative claims database in Japan. (PubMed, J Pharm Health Care Sci) - "A considerable proportion of patients were prescribed medications with DDI risk during DAA treatment. A small but notable proportion of patients were on "Contraindication (Red)" medications. Consideration of the potential DDI risks associated with comedications by healthcare professionals is advised, referring not only to package inserts but also tools such as Liverpool HEP checker to guide safe prescribing when initiating DAA therapy for HCV patients."

Journal • Hepatitis C • Hepatology • Infectious Disease • Inflammation